J&J's Tremfya Hits 94% Clinical Remission at Three Years in Crohn's Disease Trial

Johnson & Johnson reported three-year data for Tremfya (guselkumab) in moderately to severely active Crohn's disease, showing sustained clinical and endoscopic remission over the full study period. The drug achieved a 94% clinical remission rate at the three-year mark, underscoring its durability as a long-term treatment option.

A separate analysis focused on perianal fistula remission showed Tremfya achieving a 28% remission rate versus 10% for placebo, with consistent results across key patient subgroups. Fistula remission is a particularly difficult-to-treat complication of Crohn's disease, and the subgroup consistency strengthens the case for the drug's broad applicability within the patient population.